Publicacions en col·laboració amb investigadors/es de Clínica Universitaria de Navarra (166)

2024

  1. A Bioreactor for Celullarised Membrane Culture and Delivery under Sterile Conditions

    Bioengineering, Vol. 11, Núm. 8

  2. An automated network-based tool to search for metabolic vulnerabilities in cancer

    Nature Communications , Vol. 15, Núm. 1

  3. Cardiac events occurring after allogeneic hematopoietic cell transplantation with post-transplant cyclophosphamide. Study conducted on behalf of the GETH-TC

    Bone Marrow Transplantation

  4. Epigenetic-based differentiation therapy for Acute Myeloid Leukemia

    Nature Communications, Vol. 15, Núm. 1

  5. Myelodysplastic neoplasms

    Medicina Clinica, Vol. 162, Núm. 2, pp. 77-82

  6. Oxygen control in bioreactor drives high yield production of functional hiPSC-like hepatocytes for advanced liver disease modelling

    Scientific Reports, Vol. 14, Núm. 1

  7. PVR (CD155) epigenetic status mediates immunotherapy response in multiple myeloma

    Leukemia

  8. Rna-loaded nanoparticles for the treatment of hematological cancers

    Advanced Drug Delivery Reviews, Vol. 214

  9. Single-cell transcriptional profile of CD34+ hematopoietic progenitor cells from del(5q) myelodysplastic syndromes and impact of lenalidomide

    Nature Communications, Vol. 15, Núm. 1

  10. Tethered IL15-IL15Rα augments antitumor activity of CD19 CAR-T cells but displays long-term toxicity in an immunocompetent lymphoma mouse model

    Journal for immunotherapy of cancer, Vol. 12, Núm. 7

  11. Transplantation for myelofibrosis patients in the ruxolitinib era: a registry study from the Société Francophone de Greffe de Moelle et de Thérapie Cellulaire

    Bone Marrow Transplantation, Vol. 59, Núm. 7, pp. 965-973

2023

  1. Disseminated lymphadenopathy during chemotherapy for squamous cell lung carcinoma

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 41, Núm. 7, pp. 438-440

  2. Identification and experimental validation of druggable epigenetic targets in hepatoblastoma

    Journal of Hepatology, Vol. 79, Núm. 4, pp. 989-1005

  3. Phase 1 study of JNJ-64619178, a protein arginine methyltransferase 5 inhibitor, in patients with lower-risk myelodysplastic syndromes

    Leukemia Research, Vol. 134

  4. Treosulfan-Based Conditioning Regimen In Pediatric Hematopoietic Stem Cell Transplantation: A Retrospective Analysis on Behalf of the Spanish Group for Hematopoietic Transplantation and Cellular Therapy (GETH-TC)

    Transplantation and Cellular Therapy, Vol. 29, Núm. 11, pp. 702.e1-702.e11

2022

  1. Generation of NKX2.5GFP Reporter Human iPSCs and Differentiation Into Functional Cardiac Fibroblasts

    Frontiers in Cell and Developmental Biology, Vol. 9

  2. Humoral/Cellular Immune Discordance in Stem Cell Donors: Impact on Cytomegalovirus-Specific Immune Reconstitution after Related Hematopoietic Transplantation

    Transplantation and Cellular Therapy, Vol. 28, Núm. 10, pp. 703.e1-703.e8

  3. Outcome of allogeneic haematopoietic cell transplantation in eosinophilic disorders: A retrospective study by the chronic malignancies working party of the EBMT

    British Journal of Haematology

  4. Targeting the extra domain A of fibronectin for cancer therapy with CAR-T cells

    Journal for ImmunoTherapy of Cancer, Vol. 10, Núm. 8

2021

  1. Dual Targeting of G9a and DNA Methyltransferase-1 for the Treatment of Experimental Cholangiocarcinoma

    Hepatology, Vol. 73, Núm. 6, pp. 2380-2396